Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

The Role of Angiogenesis in Hepatocellular Carcinoma.

Morse MA, Sun W, Kim R, He AR, Abada PB, Mynderse M, Finn RS.

Clin Cancer Res. 2018 Oct 1. pii: clincanres.1254.2018. doi: 10.1158/1078-0432.CCR-18-1254. [Epub ahead of print]

PMID:
30274981
2.

Searching for common ground in a global disease.

Finn RS.

Hepatobiliary Surg Nutr. 2018 Aug;7(4):297-299. doi: 10.21037/hbsn.2018.04.06. No abstract available.

3.

Molecular therapies and precision medicine for hepatocellular carcinoma.

Llovet JM, Montal R, Sia D, Finn RS.

Nat Rev Clin Oncol. 2018 Oct;15(10):599-616. doi: 10.1038/s41571-018-0073-4. Review.

PMID:
30061739
4.

Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.

Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Masuda N, Im SA, Huang X, Kim S, Sun W, Iyer S, Schnell P, Bartlett CH, Johnston S.

Eur J Cancer. 2018 Sep;101:123-133. doi: 10.1016/j.ejca.2018.05.017. Epub 2018 Jul 25.

PMID:
30053671
5.

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.

Diéras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, Huang Bartlett C, Slamon DJ, Turner NC, Finn RS.

J Natl Cancer Inst. 2018 Jul 18. doi: 10.1093/jnci/djy109. [Epub ahead of print]

PMID:
30032196
6.

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators.

Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3. Erratum in: Lancet Oncol. 2018 Sep;19(9):e440.

PMID:
29875066
7.

Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.

Finn RS, Ahn DH, Javle MM, Tan BR Jr, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Chavira R, Christy-Bittel J, Barrett E, Sawyer MB, Bekaii-Saab TS.

Invest New Drugs. 2018 Dec;36(6):1037-1043. doi: 10.1007/s10637-018-0600-2. Epub 2018 May 22.

PMID:
29785570
8.

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.

Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR.

Cancer Treat Rev. 2018 Jul;68:16-24. doi: 10.1016/j.ctrv.2018.05.006. Epub 2018 May 26. Review.

9.

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.

Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J.

J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.

PMID:
29704513
10.

A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.

Court CM, Hou S, Winograd P, Segel NH, Li QW, Zhu Y, Sadeghi S, Finn RS, Ganapathy E, Song M, French SW, Naini BV, Sho S, Kaldas FM, Busuttil RW, Tomlinson JS, Tseng HR, Agopian VG.

Liver Transpl. 2018 Jul;24(7):946-960. doi: 10.1002/lt.25062.

PMID:
29624843
11.

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK.

Hepatology. 2018 Aug;68(2):723-750. doi: 10.1002/hep.29913. No abstract available.

PMID:
29624699
12.

Multiple Cranial Neuropathies From Nivolumab in a Patient With Metastatic Hepatocellular Carcinoma.

Siegel CH, Finn RS, Ho MG.

Mayo Clin Proc. 2018 Apr;93(4):540-541. doi: 10.1016/j.mayocp.2018.01.001. No abstract available.

PMID:
29622100
13.

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL.

Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.

PMID:
29433850
14.

Negative phase 3 study of 90Y microspheres versus sorafenib in HCC.

Llovet JM, Finn RS.

Lancet Oncol. 2018 Feb;19(2):e69. doi: 10.1016/S1470-2045(18)30025-1. No abstract available.

PMID:
29413470
15.

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.

Rugo HS, Diéras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CH, Iyer S, Johnston S, Ettl J, Harbeck N.

Ann Oncol. 2018 Apr 1;29(4):888-894. doi: 10.1093/annonc/mdy012.

16.

Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.

Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, Finn RS, Joy AA, Ettl J, Rugo HS, Zheng J, Wilner KD, Wang DD.

Anticancer Drugs. 2018 Mar;29(3):271-280. doi: 10.1097/CAD.0000000000000589.

17.

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.

Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, Diéras V, Moulder S, Lipatov O, Colleoni M, Cristofanilli M, Lu DR, Mori A, Giorgetti C, Iyer S, Bartlett CH, Gelmon KA.

Ann Oncol. 2018 Mar 1;29(3):669-680. doi: 10.1093/annonc/mdx797.

18.

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T.

J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.

19.

Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions.

Tak WY, Lin SM, Wang Y, Zheng J, Vecchione A, Park SY, Chen MH, Wong S, Xu R, Peng CY, Chiou YY, Huang GT, Cai J, Abdullah BJJ, Lee JS, Lee JY, Choi JY, Gopez-Cervantes J, Sherman M, Finn RS, Omata M, O'Neal M, Makris L, Borys N, Poon R, Lencioni R.

Clin Cancer Res. 2018 Jan 1;24(1):73-83. doi: 10.1158/1078-0432.CCR-16-2433. Epub 2017 Oct 10.

PMID:
29018051
20.

Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis.

Finn RS, Zhu AX, Farah W, Almasri J, Zaiem F, Prokop LJ, Murad MH, Mohammed K.

Hepatology. 2018 Jan;67(1):422-435. doi: 10.1002/hep.29486. Review.

PMID:
28881497
21.

Review of Regorafenib for the Treatment of Hepatocellular Carcinoma.

Finn RS.

Gastroenterol Hepatol (N Y). 2017 Aug;13(8):492-495. No abstract available.

22.

Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma.

Sandler KA, Veruttipong D, Agopian VG, Finn RS, Hong JC, Kaldas FM, Sadeghi S, Busuttil RW, Lee P.

Adv Radiat Oncol. 2016 Oct 29;1(4):237-243. doi: 10.1016/j.adro.2016.10.008. eCollection 2016 Oct-Dec.

23.

Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.

Gomes AS, Monteleone PA, Sayre JW, Finn RS, Sadeghi S, Tong MJ, Britten CD, Busuttil RW.

AJR Am J Roentgenol. 2017 Oct;209(4):722-732. doi: 10.2214/AJR.17.18219. Epub 2017 Jul 13.

PMID:
28705059
24.

Determination of hepatocellular carcinoma grade by needle biopsy is unreliable for liver transplant candidate selection.

Court CM, Harlander-Locke MP, Markovic D, French SW, Naini BV, Lu DS, Raman SS, Kaldas FM, Zarrinpar A, Farmer DG, Finn RS, Sadeghi S, Tomlinson JS, Busuttil RW, Agopian VG.

Liver Transpl. 2017 Sep;23(9):1123-1132. doi: 10.1002/lt.24811.

25.

Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.

Sun W, O'Dwyer PJ, Finn RS, Ruiz-Garcia A, Shapiro GI, Schwartz GK, DeMichele A, Wang D.

J Clin Pharmacol. 2017 Sep;57(9):1159-1173. doi: 10.1002/jcph.902. Epub 2017 Apr 18.

PMID:
28419480
26.

Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature.

Ono A, Goossens N, Finn RS, Schmidt WN, Thung SN, Im GY, Hoshida Y; Precision Liver Cancer Prevention Consortium.

Hepatology. 2017 Oct;66(4):1344-1346. doi: 10.1002/hep.29203. Epub 2017 Aug 26. No abstract available.

27.

Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis.

Lee MW, Raman SS, Asvadi NH, Siripongsakun S, Hicks RM, Chen J, Worakitsitisatorn A, McWilliams J, Tong MJ, Finn RS, Agopian VG, Busuttil RW, Lu DSK.

Hepatology. 2017 Jun;65(6):1979-1990. doi: 10.1002/hep.29098. Epub 2017 Apr 28.

PMID:
28170115
28.

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.

Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A.

Br J Cancer. 2017 Feb 28;116(5):575-583. doi: 10.1038/bjc.2017.10. Epub 2017 Feb 2.

29.

AASLD guidelines for the treatment of hepatocellular carcinoma.

Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA.

Hepatology. 2018 Jan;67(1):358-380. doi: 10.1002/hep.29086. No abstract available.

PMID:
28130846
30.

Palbociclib and Letrozole in Advanced Breast Cancer.

Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ.

N Engl J Med. 2016 Nov 17;375(20):1925-1936.

31.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators.

Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Erratum in: Lancet. 2017 Jan 7;389(10064):36.

PMID:
27932229
32.

The role of liver biopsy in hepatocellular carcinoma.

Finn RS.

Clin Adv Hematol Oncol. 2016 Oct;14(10):759-761. No abstract available.

PMID:
27930626
33.

Novel second-line treatments for hepatocellular carcinoma: Discussion.

Frenette CT, Lencioni R, Finn RS.

Clin Adv Hematol Oncol. 2016 Dec;14 Suppl 12(12):12-13. No abstract available.

PMID:
27930619
34.

Developing a treatment plan for hepatocellular carcinoma: the continuum of care.

Finn RS.

Clin Adv Hematol Oncol. 2016 Dec;14 Suppl 12(12):9-11. No abstract available.

PMID:
27930618
35.

The Role of Liver Biopsy in Hepatocellular Carcinoma.

Finn RS.

Gastroenterol Hepatol (N Y). 2016 Oct;12(10):628-630. No abstract available.

36.

Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.

Shi Y, Daniels-Wells TR, Frost P, Lee J, Finn RS, Bardeleben C, Penichet ML, Jung ME, Gera J, Lichtenstein A.

Cancer Res. 2016 Oct 1;76(19):5822-5831. Epub 2016 Aug 16.

37.

Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection.

Zhang B, Finn RS.

Liver Cancer. 2016 Jul;5(3):221-32. doi: 10.1159/000367763. Epub 2016 May 10. Review.

38.

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.

Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, Pinter T, Boer K, Patel R, Randolph S, Kim ST, Huang X, Schnell P, Nadanaciva S, Bartlett CH, Slamon DJ.

Breast Cancer Res. 2016 Jun 28;18(1):67. doi: 10.1186/s13058-016-0721-5.

39.

Treatment of Intermediate-Stage Hepatocellular Carcinoma.

Finn RS.

Gastroenterol Hepatol (N Y). 2015 Aug;11(8):545-7. No abstract available.

40.

Unilateral Pleural Effusions with More Than One Apparent Etiology. A Prospective Observational Study.

Bintcliffe OJ, Hooper CE, Rider IJ, Finn RS, Morley AJ, Zahan-Evans N, Harvey JE, Skyrme-Jones AP, Maskell NA.

Ann Am Thorac Soc. 2016 Jul;13(7):1050-6. doi: 10.1513/AnnalsATS.201601-082OC.

PMID:
27064965
41.

Treating cancer with selective CDK4/6 inhibitors.

O'Leary B, Finn RS, Turner NC.

Nat Rev Clin Oncol. 2016 Jul;13(7):417-30. doi: 10.1038/nrclinonc.2016.26. Epub 2016 Mar 31. Review.

PMID:
27030077
42.

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.

Bell T, Crown JP, Lang I, Bhattacharyya H, Zanotti G, Randolph S, Kim S, Huang X, Huang Bartlett C, Finn RS, Slamon D.

Curr Med Res Opin. 2016 May;32(5):959-65. doi: 10.1185/03007995.2016.1157060. Epub 2016 Mar 2.

PMID:
26894413
43.

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.

Finn RS, Aleshin A, Slamon DJ.

Breast Cancer Res. 2016 Feb 9;18(1):17. doi: 10.1186/s13058-015-0661-5. Review.

44.

Treatment of intermediate-stage hepatocellular carcinoma.

Finn RS.

Clin Adv Hematol Oncol. 2015 Aug;13(8):501-3. No abstract available.

PMID:
26351811
45.

Doctors learn new tricks, but do they remember them? Lack of effect of an educational intervention in improving Oxygen prescribing.

Myers H, Taylor J, Finn RS, Beckert L.

Respirology. 2015 Nov;20(8):1229-32. doi: 10.1111/resp.12614. Epub 2015 Aug 31.

46.

Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer.

Lin ML, Patel H, Remenyi J, Banerji CR, Lai CF, Periyasamy M, Lombardo Y, Busonero C, Ottaviani S, Passey A, Quinlan PR, Purdie CA, Jordan LB, Thompson AM, Finn RS, Rueda OM, Caldas C, Gil J, Coombes RC, Fuller-Pace FV, Teschendorff AE, Buluwela L, Ali S.

Oncotarget. 2015 Aug 28;6(25):21685-703.

47.

Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma.

Raoul JL, Park JW, Kang YK, Finn RS, Kim JS, Yeo W, Polite BN, Chao Y, Walters I, Baudelet C, Lencioni R.

Liver Cancer. 2014 Oct;3(3-4):439-50. doi: 10.1159/000343872. Review.

48.

Advances in targeted therapies for hepatocellular carcinoma in the genomic era.

Llovet JM, Villanueva A, Lachenmayer A, Finn RS.

Nat Rev Clin Oncol. 2015 Aug;12(8):436. doi: 10.1038/nrclinonc.2015.121. Epub 2015 Jun 23. No abstract available.

PMID:
26099984
49.

Adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma.

Bodzin AS, Finn RS, Busuttil RW.

Hepatobiliary Pancreat Dis Int. 2015 Jun;14(3):234-5. No abstract available.

PMID:
26063022
50.

Advances in targeted therapies for hepatocellular carcinoma in the genomic era.

Llovet JM, Villanueva A, Lachenmayer A, Finn RS.

Nat Rev Clin Oncol. 2015 Jul;12(7):408-24. doi: 10.1038/nrclinonc.2015.103. Epub 2015 Jun 9. Review. Erratum in: Nat Rev Clin Oncol. 2015 Aug;12(8):436.

PMID:
26054909

Supplemental Content

Support Center